

# Alberto Floris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6775962/publications.pdf>

Version: 2024-02-01

40  
papers

775  
citations

623699

14  
h-index

526264

27  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1126  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. <i>Clinical Rheumatology</i> , 2022, 41, 19-31.	2.2	28
2	Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic. <i>Rheumatology</i> , 2022, 61, 1795-1801.	1.9	22
3	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic Disease (CORDIS) Study Group. <i>European Journal of Internal Medicine</i> , 2022, 96, 60-65.	2.2	12
4	Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity. <i>Rheumatology</i> , 2022, 62, 116-123.	1.9	1
5	Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review. <i>BioDrugs</i> , 2021, 35, 175-186.	4.6	2
6	Gene Expression Profiling of Monozygotic Twins Affected by Psoriatic Arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 23-29.	1.6	2
7	Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs. <i>Medicine (United States)</i> , 2021, 100, e25481.	1.0	7
8	Targeted Therapies in Axial Psoriatic Arthritis. <i>Frontiers in Genetics</i> , 2021, 12, 689984.	2.3	1
9	Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoud's arthropathy and a distinctive MRI pattern. <i>Rheumatology</i> , 2021, 60, 4218-4228.	1.9	5
10	Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage. <i>Arthritis Care and Research</i> , 2020, 72, 1794-1799.	3.4	13
11	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. <i>Rheumatology</i> , 2020, 59, 2272-2281.	1.9	25
12	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 278.	3.5	7
13	Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. <i>Rheumatology</i> , 2020, 59, 3622-3632.	1.9	39
14	<p><Assessment Of Circulating Endothelial Cells And Their Progenitors As Potential Biomarkers Of Disease Activity And Damage Accrual In Behçet's Syndrome</p><p><. Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 219-227.	1.6	2
15	THU0299&#x2013;PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHÇET'S SYNDROME: A MULTICENTER STUDY. , 2019, , .		0
16	SAT0035&#x2013;IS PHARMACOLOGICAL CLINICAL REMISSION SYNONYMOUS WITH BIOLOGICAL INACTIVE DISEASE? DIFFERENTIAL GENE EXPRESSION ANALYSIS IN RHEUMATOID ARTHRITIS AND HEALTHY CONTROLS. , 2019, , .		0
17	SAT0240&#x2013;DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÇET'S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .		0
18	FRI0357&#x2013;DRUG-INDUCED REMISSION AND SUBCLINICAL ACTIVITY IN PSORIATIC ARTHRITIS: TRANSCRIPTIONAL PROFILING TO CHARACTERIZE THE DISEASE STATE. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	THU0095â€¦CIGARETTE SMOKING AS PREDICTOR OF INADEQUATE RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS NAËVE TO DMARDS. , 2019, , .		0
20	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. Rheumatology, 2018, 57, 227-235.	1.9	101
21	Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus. Lupus, 2018, 27, 190-198.	1.6	39
22	The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology, 2018, 57, 112-119.	1.9	53
23	ALF-1 gene does not confer susceptibility to Behçet's disease: Analysis of extended haplotypes in Sardinian population. PLoS ONE, 2018, 13, e0204250.	2.5	4
24	Polymyalgia rheumatica: an autoinflammatory disorder?. RMD Open, 2018, 4, e000694.	3.8	15
25	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Mediators of Inflammation, 2018, 2018, 1-11.	3.0	56
26	Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis. RMD Open, 2018, 4, e000597.	3.8	9
27	Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. Journal of Rheumatology, 2018, 45, 1256-1262.	2.0	10
28	Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmunity Reviews, 2017, 16, 244-252.	5.8	41
29	Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease. Rheumatology, 2017, 56, 2038-2039.	1.9	2
30	Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. Reumatismo, 2017, 69, 175-183.	0.9	12
31	Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 167-170.	1.6	4
32	Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Research and Therapy, 2017, 19, 247.	3.5	66
33	Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmunity Reviews, 2016, 15, 656-663.	5.8	51
34	Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001â€“2012. Rheumatology International, 2016, 36, 73-81.	3.0	12
35	Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001â€“2012. Lupus, 2016, 25, 28-37.	1.6	28
36	Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis). ImmunoTargets and Therapy, 2015, 4, 185.	5.8	9

#	ARTICLE	IF	CITATIONS
37	New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol. Journal of rheumatology Supplement, The, 2015, 93, 70-72.	2.2	10
38	Killerâ€Cell Immunoglobulinâ€Like Receptors (<scp>KIR</scp>) and <scp>HLA</scp>â€Class <scp>I</scp> Heavy Chains in Ankylosing Spondylitis. Drug Development Research, 2014, 75, S15-9.	2.9	11
39	Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort. Autoimmunity Reviews, 2014, 13, 873-879.	5.8	71
40	277â€fUsing the Birmingham Vasculitis Activity Score as a Screening Tool in Patients with Suspected Vasculitis. Rheumatology, 0, , .	1.9	0